Breast Invasive Carcinoma
1,098 breast tumors measured twelve ways across GDC and IDC, with treatment outcome on 64% of cases - the most reused dataset in this corpus and still the reference cohort for method development.
Can it answer your research question?
6 of 6 supportedOverall survival
SupportedVital status and time are populated; median follow-up 2.3 years; 1,096 cases with follow-up; endpoints: overall survival, progression-free interval.API
Progression or recurrence
SupportedA time to event is derivable: progression-free interval;
progression_or_recurrenceis informative for 9% of cases.APITreatment response
Supporteddisease_responseis populated for 97% of cases; criteria: complete response, progressive disease.APIWhich drug was given
Supportedtherapeutic_agentsis recorded for 71% of cases.APIStage-adjusted modelling
Supportedajcc_pathologic_stageis informative for 99% of cases.APIAnalysis by race or ethnicity
SupportedRace is informative for 91% of cases.API
At a glance
Every percentage is the repository’s own record of what is filled inSubjectCALC
As filed by the repository
Who is in the cohortAPI
- Sex1,085 female · 12 male · 1 no value recorded
- Race757 white · 183 black or african american · 61 asian · 1 1 other · 95 not reported · 1 no value recorded
- Ethnicity884 not hispanic or latino · 39 hispanic or latino · 166 not reported · 8 unknown · 1 no value recorded
- Vital status945 alive · 152 dead · 1 no value recorded
Age at diagnosis
What was measured, and on how many
- SNP genotyping array (copy number, germline)1,098 of 1,098 · 100%
- Clinical1,098 of 1,098 · 100%
- DICOM medical imaging1,098 of 1,098 · 100%
- DNA methylation array1,097 of 1,098 · >99%
- Bulk RNA sequencing1,095 of 1,098 · >99%
- microRNA sequencing1,079 of 1,098 · 98%
- Whole exome sequencing1,072 of 1,098 · 98%
- Whole-slide diagnostic images1,062 of 1,098 · 97%
- Whole genome sequencing952 of 1,098 · 87%
- Somatic Structural Variation927 of 1,098 · 84%
- Reverse phase protein array881 of 1,098 · 80%
- ATAC sequencing (chromatin accessibility)74 of 1,098 · 7%
Platform, files and data levels
| Assay | Platform | Files | Levels |
|---|---|---|---|
| SNP genotyping array (copy number, germline)API | illumina | 14,329 | - |
| ClinicalAPI2 | - | 2,288 | - |
| DICOM medical imagingAPI | - | - | DICOM series |
| DNA methylation arrayAPI | illumina | 3,714 | - |
| Bulk RNA sequencingAPI | illumina | 11,079 | - |
| microRNA sequencingAPI | illumina | 3,621 | - |
| Whole exome sequencingAPI | illumina | 17,050 | - |
| Whole-slide diagnostic imagesAPI2 | illumina | 1,133 | - |
| Whole genome sequencingAPI2 | illumina | 13,031 | - |
| Somatic Structural VariationAPI | - | 3,128 | - |
| Reverse phase protein arrayAPI | illumina | 919 | - |
| ATAC sequencing (chromatin accessibility)API | illumina | 75 | - |
How complete all 29 clinical fields are - 15 informative for at least 80% of cases
Outcome
Follow-up
Treatment
Diagnosis
Demographics
Access
Data Access Request through dbGaP using an eRA Commons account; institutional signing official approval required
- Open components
- 27,931 open-access files
- Controlled components
- 43,492 controlled-access files
- Typical turnaround
- days to a few weeks after signing official approval
- License
- NIH Genomic Data Sharing Policy terms
- Citation requirement
- Cite the dataset accession and the program's publication guidelines; see the GDC publication policy.
What it is good for
Written and checked by a reviewer, not generated from metadata.
1. Does a new computational method reproduce established breast cancer molecular subtypes?
Answerable as shippedn ≈ 1,080HUMANExpression, methylation, copy number, microRNA and protein array data on largely the same 1,098 tumors, with subtype assignments established across hundreds of prior papers. This is the standard benchmark, and the density of prior work is the point.
Statistical note: Because so many methods have been tuned on this cohort, strong performance here is weak evidence of generalization. Pair it with an external cohort.
NeedsBulk RNA sequencingDNA methylationCopy numberReverse phase protein array2. Which molecular features are associated with response to specific systemic therapies?
Answerable as shippedn ≈ 700HUMANTherapeutic agents are recorded for 71% of cases - cyclophosphamide, tamoxifen, anastrozole, paclitaxel and doxorubicin are the commonest - and a treatment outcome field is populated for 64%. Combined with expression on 1,095 cases this supports agent-stratified response analysis.
Statistical note: Treatment was not randomized and is confounded with stage, subtype and era of care. Any agent comparison needs explicit confounding control and should be framed as associative.
NeedsBulk RNA sequencingTreatment recordsdiagnoses.treatments.therapeutic_agentsdiagnoses.treatments.treatment_outcome3. Do radiology or pathology image features add prognostic information beyond molecular data?
Needs another datasetn ≈ 1,098HUMANImaging for these same patients is held in the Imaging Data Commons and is openly downloadable, while the molecular data sit in the GDC. Joining them gives a multimodal cohort most users never realise is available.
Statistical note: Imaging coverage is not complete across the cohort; build the intersection first and check it is not biased by site or era.
NeedsRadiology imagingHistopathology slidesBulk RNA sequencing4. What distinguishes long-term survivors, given a median follow-up of 27.1 months?
Answerable as shippedn ≈ 1,097HUMANVital status is informative for 99.9% of cases and follow-up time is computable, giving a clean overall survival endpoint on a large cohort.
Statistical note: Breast cancer events accrue over a decade or more, and the median patient here is followed under three years, although a minority reach twenty years. Late-recurrence questions are underpowered.
NeedsClinical dataOutcome dataBulk RNA sequencing
What it cannot tell you
Written by a reviewer against the source, not inferred from what is missing.
Median follow-up is 27.1 months across 1,096 of 1,098 cases, though the maximum reaches 282 months. Breast cancer, particularly hormone receptor positive disease, recurs over ten to twenty years, so the median patient is observed through only the early part of the natural history.
Affects: Late recurrence; Ten-year survival; Endocrine resistance over time
Mitigation: Use restricted mean survival time; do not extrapolate beyond observed follow-up.
Treatment is observational and unrandomised, recorded retrospectively, and reflects standards of care from the late 2000s. Modern regimens including CDK4/6 inhibitors, antibody-drug conjugates and immunotherapy are absent.
Affects: Predictive biomarker claims; Contemporary treatment relevance
Mitigation: Frame findings as historical-cohort associations rather than predictive claims.
757 of 1,098 patients are recorded as white and 183 as Black or African American, with 95 not reported. Male breast cancer is present only in very small numbers.
Affects: Disparities research beyond the two largest groups; Male breast cancer
Mitigation: The 183 Black patients support some disparities work but with limited power for subtype-stratified analysis.
Methylation uses HM450 and HM27 arrays and copy number uses Affymetrix SNP 6.0 - platforms no longer in routine use, which complicates integration with contemporary data.
Affects: Cross-cohort integration with modern platforms
Mitigation: Use probe-level harmonization and restrict to shared features.
43,492 of 71,423 files are controlled; derived matrices are open.
Affects: Raw sequence analysis
Mitigation: Most secondary analyses run entirely on the open derived files.
Not appropriate for
- Evaluating modern therapies such as CDK4/6 inhibitors or immunotherapy. - Treatment predates these agents; they do not appear in the cohort.HUMAN
- Estimating breast cancer incidence or population survival. - A convenience sample from participating centres, with no denominator.HUMAN
- Claiming a novel method generalizes on the basis of TCGA-BRCA performance alone. - The cohort has been used so extensively for method development that performance on it is partly a measure of collective overfitting.HUMAN
Who has used it
Articles that analyzed these data, counted separately from articles that only cited the paper. Only the first counts as reuse.
What articles did with it
- Cited the paper9,914
- Mentioned the dataset269
- Accession found in text0
- Declared using it313
- Analyzed the data2,373
Against comparable datasets
- Analyzed it2,373
- Expected~412
- Reuse is within the expected range for comparable datasets (index +2.52).
Original publication
Articles that analyzed the data
Community examples
Share your exampleAnalyses someone ran on these data end to end, each with a receipt recording when it ran, against which packages and for how long.
Which classes of analysis do this cohort's clinical records actually support, and which are ruled out before I request access?
Audit whether this dataset can answer your question
- A GDC project identifier
- Network access to api.gdc.cancer.gov
- Per-field coverage table separating populated from informative values
- Assay coverage as a percentage of the cohort
- A yes/no verdict for six common analysis classes
- A chart contrasting populated with informative coverage, field by field
Steps
- Fetch project summary and per-assay case counts
- Request facet counts for the clinical fields that gate common analyses
- Separate absent fields from fields populated with non-answers
- Flag one-to-many fields where per-case percentages cannot be inferred
- Retrieve case-level fields and test whether a survival endpoint is derivable
- Print a verdict for each analysis class
Which molecular and clinical factors are associated with survival?
Overall survival from open data, with the endpoint derived correctly
- Open GDC clinical records, no account required
- lifelines, pandas, numpy
- Kaplan-Meier estimates with survival at 12, 36 and 60 months
- Log-rank test between stage groups
- Multivariable Cox model with concordance
- A Kaplan-Meier plot of overall survival, stratified by stage at diagnosis
Steps
- Retrieve case-level clinical fields including all three follow-up locations
- Derive time and event, guarding against GDC sentinel values
- Report how many cases are dropped and why
- Fit Kaplan-Meier and a stage-stratified log-rank test
- Fit a multivariable Cox model adjusting for age and stage
Which cohorts have both imaging and molecular data on the same patients, and how many patients actually carry both?
Join the same patients across two NCI repositories
- Open GDC and IDC APIs, no account required
- pandas
- Patient-level intersection between a GDC project and an IDC collection
- Counts of molecular-only, imaging-only and joined patients
- A map of every cohort present in both repositories
- A chart comparing molecular and imaging patient counts per linkable cohort
Steps
- Retrieve patient identifiers from the GDC project
- Query IDC's public SQL endpoint for the collection's patient identifiers
- Intersect on the shared barcode and quantify the overlap
- Sweep every GDC project against every IDC collection
Start here
Starter code generated from this record’s own identifiers, then the access steps.
Get the data in code
GDC: list open files and download thempython
import json, requests
PROJECT = "TCGA-BRCA"
filters = {"op": "and", "content": [
{"op": "in", "content": {"field": "cases.project.project_id", "value": [PROJECT]}},
{"op": "in", "content": {"field": "access", "value": ["open"]}},
]}
params = {"filters": json.dumps(filters),
"fields": "file_id,file_name,data_category,data_type,file_size",
"size": "10000", "format": "JSON"}
files = requests.get("https://api.gdc.cancer.gov/files", params=params, timeout=60).json()["data"]["hits"]
print(len(files), "open files")
# Write a manifest and fetch with the GDC client (https://gdc.cancer.gov/access-data/gdc-data-transfer-tool)
with open("manifest.txt", "w") as fh:
fh.write("id\n" + "\n".join(f["file_id"] for f in files))
# $ gdc-client download -m manifest.txtGDC: clinical table for every casepython
import json, requests
filters = {"op": "in", "content": {"field": "project.project_id", "value": ["TCGA-BRCA"]}}
params = {"filters": json.dumps(filters), "size": "5000", "format": "TSV",
"fields": ",".join([
"submitter_id", "demographic.vital_status", "demographic.days_to_death",
"diagnoses.days_to_last_follow_up", "diagnoses.ajcc_pathologic_stage",
"diagnoses.treatments.treatment_type", "diagnoses.treatments.treatment_outcome"])}
tsv = requests.get("https://api.gdc.cancer.gov/cases", params=params, timeout=60).text
open("TCGA-BRCA_clinical.tsv", "w").write(tsv)IDC: pull the DICOM collection with idc-indexpython
from idc_index import IDCClient
COLLECTION = "tcga_brca"
client = IDCClient()
series = client.index[client.index["collection_id"] == COLLECTION] # one row per DICOM series
print(len(series), "series,", series["PatientID"].nunique(), "patients,",
round(series["series_size_MB"].sum() / 1024, 1), "GB")
print(series["Modality"].value_counts().to_dict())
# Everything above is an index lookup and costs nothing. Uncomment to pull the pixels;
# the client refuses up front if the disk cannot hold them.
# client.download_from_selection(collection_id=COLLECTION, downloadDir="./tcga_brca")This page as data: limitations firstbash
curl -s https://cd2s.vercel.app/data/datasets/gdc-tcga-brca.json | python3 -c '
import json, sys
r = json.load(sys.stdin)
for l in r["limitations"]:
print(l["severity"].upper(), "-", l["statement"][:120])
print("survival endpoint:", r["longitudinal"]["has_survival_endpoint"], "| treatment response:", r["longitudinal"]["has_treatment_response"])'Access steps
- Download open derived matrices from the GDCFor people
Expression, copy number, methylation and clinical files need no account.
https://portal.gdc.cancer.gov/projects/TCGA-BRCAcurl -s 'https://api.gdc.cancer.gov/files' --get \ --data-urlencode 'filters={"op":"and","content":[ {"op":"in","content":{"field":"cases.project.project_id","value":["TCGA-BRCA"]}}, {"op":"in","content":{"field":"access","value":["open"]}}, {"op":"in","content":{"field":"data_type","value":["Gene Expression Quantification"]}}]}' \ --data-urlencode 'fields=file_id,file_name,cases.submitter_id' \ --data-urlencode 'size=2000&format=TSV' > brca_expression_files.tsv - Add the imaging from the Imaging Data Commons if you need itFor people
Same patients, different repository, also open. Most users never make this join.
https://portal.imaging.datacommons.cancer.gov/explore/?collection_id=tcga_brca - Request controlled access only if you need sequence-level dataFor peoplehttps://gdc.cancer.gov/access-data/obtaining-access-controlled-data
- Query the project from code, with no credentialsFor agents
The file index is public even where files are not, so an agent can size the cohort before anyone requests access.
https://docs.gdc.cancer.gov/API/Users_Guide/Getting_Started/curl -s 'https://api.gdc.cancer.gov/files' --get \ --data-urlencode 'filters={"op":"in","content":{"field":"cases.project.project_id","value":["TCGA-BRCA"]}}' \ --data-urlencode 'fields=file_id,file_name,data_type' \ --data-urlencode 'size=10000' --data-urlencode 'format=TSV' - Pass the token when the agent needs controlled filesFor agents
Without a token, an API query may return only the open subset. Compare returned counts with the record before treating them as the whole cohort.
https://docs.gdc.cancer.gov/API/Users_Guide/Getting_Started/curl -H "X-Auth-Token: $GDC_TOKEN" https://api.gdc.cancer.gov/data/<file_id>
Provenance
All of it, and more, is in this record’s JSON.
Identifiers
Versions and verification
- Released
- 1 Jan 2013
- Metadata retrieved
- 18 Sept 2026
- Review status
- Project-curatedCD2S project curation on 18 Sept 2026
- Data generation funding
- Funded data generation
Funding
Funded data generation
- U24CA144025Harvard Genome Characterization CenterRaju S. KucherlapatiAPI
- U24CA143883Integrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC)Rehan Akbani, GORDON B. MILLSAPI
- U24CA143882The USC-JHU Cancer Epigenome Characterization CenterSTEPHEN B. BAYLIN, Daniel Joseph WeisenbergerAPI
- U24CA143867Genome Characterization Center (GCC)Stacey Gabriel, Matthew L. MeyersonAPI
- U24CA143866Cancer transcriptome characterization using massively parallel DNA sequencingMarco Antonio MarraAPI
- U24CA143858UCSC-Buck Inst. Genome Data Analysis Center for TCGA Research Network (GDAC)Christopher Benz, DAVID H HAUSSLERAPI
- U24CA143848Gene Expression Patterns in Human Tumors Identified Using Transcript SequencingDavid N Hayes, CHARLES M PEROUAPI
- U24CA143845The Cancer Genome Atlas Data Analysis CenterLYNDA CHIN, GAD A GETZAPI
- U24CA143840MSKCC Center for Translational Cancer Genomic AnalysisMarc Ladanyi, CHRIS SANDERAPI
- U24CA143835Center for Systems Analysis of the Cancer RegulomeILYA SHMULEVICHAPI